In doxorubicin resistant gastric cancer (SGC7901/DOX) cells, resveratrol treatment improved doxorubicin sensitivity, mitigated the aggressive biological features, as well as promoted cell apoptosis in vitro and in vivo by inhibiting EMT and PTEN/AKT pathway [216]. The gene discussed is AKT1; the disease is gastric cancer.